[Effects of miR-100-5p on proliferation and apoptosis of acute myeloid leukemia cells and the underlying molecular mechanism].
1/5 보강
[OBJECTIVES] To investigate whether miR-100-5p regulates the proliferation and apoptosis of acute myeloid leukemia (AML) cells by targeting Tribbles pseudokinase 1 (TRIB1).
APA
Fan XR, Yang Y, et al. (2026). [Effects of miR-100-5p on proliferation and apoptosis of acute myeloid leukemia cells and the underlying molecular mechanism].. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 28(1), 99-106. https://doi.org/10.7499/j.issn.1008-8830.2503192
MLA
Fan XR, et al.. "[Effects of miR-100-5p on proliferation and apoptosis of acute myeloid leukemia cells and the underlying molecular mechanism].." Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, vol. 28, no. 1, 2026, pp. 99-106.
PMID
41582755 ↗
Abstract 한글 요약
[OBJECTIVES] To investigate whether miR-100-5p regulates the proliferation and apoptosis of acute myeloid leukemia (AML) cells by targeting Tribbles pseudokinase 1 (TRIB1).
[METHODS] Peripheral blood was collected from 16 healthy children (control group) and 16 children with AML (AML group). HL-60 cells were divided into seven groups: blank, mimic negative control (mimic NC), miR-100-5p mimic, small interfering RNA negative control (si-NC), si-TRIB1, miR-100-5p mimic + TRIB1 overexpression plasmid negative control (OE-NC), and miR-100-5p mimic + TRIB1 overexpression plasmid (OE-TRIB1). The expression of miR-100-5p and TRIB1 mRNA in peripheral blood and HL-60 cells was detected by quantitative real-time PCR. Cell proliferation was assessed by 5-ethynyl-2'-deoxyuridine (EdU) staining and the cell counting kit-8 (CCK-8) assay (OD). Apoptosis was analyzed by flow cytometry. Protein levels of TRIB1, proliferating cell nuclear antigen (PCNA), p53, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) were determined by Western blot. The targeting relationship between miR-100-5p and TRIB1 was validated by a dual-luciferase reporter assay.
[RESULTS] Compared with the control group, miR-100-5p expression was decreased and TRIB1 mRNA expression was increased in the peripheral blood of the AML group (<0.05). Compared with the blank and mimic NC groups, the miR-100-5p mimic group showed higher miR-100-5p expression, apoptosis rate, and p53 protein, and lower TRIB1 mRNA expression, EdU-positive rate, OD value, and TRIB1, PCNA, PD-1, and PD-L1 proteins (<0.05). Compared with the blank and si-NC groups, the si-TRIB1 group exhibited reduced TRIB1 mRNA expression, EdU-positive rate, OD value, and TRIB1, PCNA, PD-1, and PD-L1 proteins, together with increased apoptosis rate and p53 protein (<0.05). Compared with the miR-100-5p mimic and miR-100-5p mimic + OE-NC groups, the miR-100-5p mimic + OE-TRIB1 group had elevated TRIB1 mRNA expression, EdU-positive rate, OD value, and TRIB1, PCNA, PD-1, and PD-L1 proteins, and reduced apoptosis rate and p53 protein (<0.05). Compared with the TRIB1-WT + mimic NC group, luciferase activity was decreased in the TRIB1-WT + miR-100-5p mimic group (<0.05).
[CONCLUSIONS] Overexpression of miR-100-5p inhibits proliferation and induces apoptosis of HL-60 cells by downregulating TRIB1.
[METHODS] Peripheral blood was collected from 16 healthy children (control group) and 16 children with AML (AML group). HL-60 cells were divided into seven groups: blank, mimic negative control (mimic NC), miR-100-5p mimic, small interfering RNA negative control (si-NC), si-TRIB1, miR-100-5p mimic + TRIB1 overexpression plasmid negative control (OE-NC), and miR-100-5p mimic + TRIB1 overexpression plasmid (OE-TRIB1). The expression of miR-100-5p and TRIB1 mRNA in peripheral blood and HL-60 cells was detected by quantitative real-time PCR. Cell proliferation was assessed by 5-ethynyl-2'-deoxyuridine (EdU) staining and the cell counting kit-8 (CCK-8) assay (OD). Apoptosis was analyzed by flow cytometry. Protein levels of TRIB1, proliferating cell nuclear antigen (PCNA), p53, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) were determined by Western blot. The targeting relationship between miR-100-5p and TRIB1 was validated by a dual-luciferase reporter assay.
[RESULTS] Compared with the control group, miR-100-5p expression was decreased and TRIB1 mRNA expression was increased in the peripheral blood of the AML group (<0.05). Compared with the blank and mimic NC groups, the miR-100-5p mimic group showed higher miR-100-5p expression, apoptosis rate, and p53 protein, and lower TRIB1 mRNA expression, EdU-positive rate, OD value, and TRIB1, PCNA, PD-1, and PD-L1 proteins (<0.05). Compared with the blank and si-NC groups, the si-TRIB1 group exhibited reduced TRIB1 mRNA expression, EdU-positive rate, OD value, and TRIB1, PCNA, PD-1, and PD-L1 proteins, together with increased apoptosis rate and p53 protein (<0.05). Compared with the miR-100-5p mimic and miR-100-5p mimic + OE-NC groups, the miR-100-5p mimic + OE-TRIB1 group had elevated TRIB1 mRNA expression, EdU-positive rate, OD value, and TRIB1, PCNA, PD-1, and PD-L1 proteins, and reduced apoptosis rate and p53 protein (<0.05). Compared with the TRIB1-WT + mimic NC group, luciferase activity was decreased in the TRIB1-WT + miR-100-5p mimic group (<0.05).
[CONCLUSIONS] Overexpression of miR-100-5p inhibits proliferation and induces apoptosis of HL-60 cells by downregulating TRIB1.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.